pharmaphorum8d
A history of Bayer
Dr. Marijn Dekkers, Bayer chief executive, 2010-2016 However, before we get into the history of this German pharmaceutical company ... own Bayer Cross corporate logo. This was under the leadership ...
BioPharma Dive23h
Eisai wins over European regulators on Alzheimer’s drug Leqembi
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
FiercePharma6h
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Investing4d
Earnings call: Eisai reports growth with focus on Alzheimer's treatment
Eisai Company Limited (4523.T) has reported a modest revenue increase in its Q2 Fiscal 2024 earnings call, with significant developments in its Alzheimer's disease treatments. The pharmaceutical ...
Zacks.com on MSN6h
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...
Investing4d
Earnings call: Eisai reports growth with focus on Alzheimer's treatment
Eisai Company Limited (4523.T) has reported a modest revenue increase in its Q2 Fiscal 2024 earnings call, with significant developments in its Alzheimer's disease treatments. The pharmaceutical giant ...
Investing4d
Earnings call: Eisai reports steady growth and LEQEMBI launch success
Eisai Company Limited (ESALY (OTC:ESAIY)) has reported a modest revenue growth of 3% year-on-year in its Q2 Fiscal 2024 earnings call, totaling JPY 385 billion. The pharmaceutical segment saw a 5% ...
Investing4d
Earnings call: Eisai reports steady growth and LEQEMBI launch success
Eisai Company Limited (ESALY (OTC:ESAIY)) has reported a modest revenue growth of 3% year-on-year in its Q2 Fiscal 2024 earnings call, totaling JPY 385 billion. The pharmaceutical segment saw a 5% ...
Asia One10d
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
The company also supports investment in drug discovery technologies in other areas, where significant future innovations are anticipated. As anAMED-registered VC, Eisai Innovation, Inc. aims to ...